Healthcare Industry News: Caris Life Sciences
News Release - August 31, 2010
Dr. Les Paul Joins Caris Life Sciences as Senior Vice President, Medical AffairsFast-Growing Biosciences Company Forms Medical Affairs Group, Headed by a 30-Year Veteran
IRVING, Texas, Aug. 31, 2010 -- (Healthcare Sales & Marketing Network) -- Caris Life Sciences(TM), Inc., a leading biosciences company focused on enabling precise and personalized healthcare through the highest quality anatomic pathology, molecular profiling, and blood-based diagnostic technologies, announced today that Les Paul, MD, MS has joined the company as Senior Vice President, Medical Affairs.
In this position, Dr. Paul will lead educational and informational efforts to support clinicians using the company's proprietary products, including the Caris Target Now(R) molecular profiling and therapeutic guidance test, which provides treatment options associated with clinical benefit for cancer patients based on the molecular profile and genetic make-up of the specific tumor; and the Carisome(TM) Platform, a proprietary, blood-based technology currently being developed for earlier, more accurate and less invasive testing for cancer and other complex diseases.
Dr. Paul will also assume responsibility for the direction of post-market study activity designed to further demonstrate the clinical value and patient care benefits derived from the company's personalized medical services. Dr. Paul will guide these efforts to help clients provide optimal treatment to their patients.
"Caris is aware that game-changing technologies, like those we provide, will create education challenges in the healthcare marketplace," said Jerry Martino, Executive Vice President and Chief Operations Officer. "Training and other educational opportunities, as well as ongoing communication and collaboration with the clients using these new technologies, will be critical not only to the success of our products, but to the improvement of patient care."
Dr. Paul brings 30 years of extraordinary experience and a top-notch reputation to this new position, including a range of experiences as a practicing physician, chief medical officer and leader of medical affairs. Most recently, he served as the Head of Clinical and Scientific Affairs for the National Pharmaceutical Council in Washington, D.C. Prior to that role, he led significant medical affairs organizations for both Novartis and AstraZeneca. Dr. Paul holds a bachelor of science from the University of Illinois, Chicago; a doctor of medicine from the University of Illinois, College of Medicine, Chicago; and a master of health administration and preventive medicine from the University of Wisconsin, Madison. He is board certified in internal medicine and pulmonary diseases.
About Caris Life Sciences
Caris Life Sciences, a leading biosciences company, specializes in the development and commercialization of the highest quality anatomic pathology, molecular profiling, and blood-based diagnostic technologies, in the fields of oncology, dermatopathology, hematopathology, gastrointestinal pathology and urologic pathology. The company provides academic-caliber consultations for thousands of patients a day, through its industry-leading team of expert, subspecialty pathologists. Caris also offers advanced molecular analyses of patient samples through prognostic testing services and genomic, transcriptomic, and proteomic profiling to assist physicians in their treatment of cancer. Currently, Caris is developing the Carisome(TM) platform, a proprietary, blood-based technology for diagnosis, prognosis, and theranosis of cancer and other complex diseases. The company is headquartered in the Dallas metroplex, operates laboratories in the Dallas, Phoenix and Boston metro areas and is entering the European markets through its first international location, in Switzerland. For more information, visit www.carislifesciences.com.
Source: Caris Life Sciences
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.
Related News ItemsCaris Life Sciences Appoints Steven D. Averbuch, M.D., to Its Scientific Advisory Board
Caris Life Sciences Partners with Debiopharm International SA to Develop Companion Diagnostic for Detection of Rare FGFR Fusions Using Novel Molecular Intelligence (MI) Transcriptome(TM)
Caris Life Sciences Receives FDA Breakthrough Device Designation for MI Transcriptome(TM) Companion Diagnostic Test